Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-10-2013 | Original Paper

Expression of E-cadherin, Twist, and p53 and their prognostic value in patients with oral squamous cell carcinoma

Authors: Chi-Chen Fan, Tao-Yeuan Wang, Yen-An Cheng, Shih Sheng Jiang, Chien-Wen Cheng, Alan Yueh-Luen Lee, Ting-Yu Kao

Published in: Journal of Cancer Research and Clinical Oncology | Issue 10/2013

Abstract

Purpose

Epithelial–mesenchymal transition (EMT) and p53 play important roles in controlling cancer invasion and metastasis. However, discrepancies still exist in the relationship between the expression of an epithelial marker E-cadherin and predicting short survival of patients in many types of cancer. In this study, we aimed to determine the levels of E-cadherin, Twist, and p53 in tumor tissues from patients with oral squamous cell carcinoma (OSCC) and their clinical significances.

Methods

The protein expression of 112 OSCC tumor and 16 benign tissues was examined by immunohistochemistry staining. Overall survival rates of 112 OSCC patients were measured using Kaplan–Meier estimates and the log-rank tests.

Results

E-cadherin and p53 downregulation were found in 70 of 112 (62.5 %) and 66 of 112 (59.0 %), respectively, and Twist overexpression was found in 72 of 112 (64.3 %) studied cases of OSCC patients. Expression of E-cadherin was significantly associated with tumor location (P = 0.004) and mortality (P = 0.010). Patients with lower E-cadherin expression (P = 0.024), betel quid chewing (P = 0.006), smoking (P = 0.001), tumor size >2 cm (P = 0.001), advanced tumor stage (P = 0.043), and recurrence (P < 0.001) exhibited a poorer outcome. Multivariate analysis showed that E-cadherin is an independent marker for survival prediction. Additionally, low E-cadherin expression is significantly correlated with low p53 expression.

Conclusions

E-cadherin is an independent marker for survival prediction in OSCC. Co-evaluation of E-cadherin and p53 expression might be a valuable tool for predicting OSCC patient outcome.

Aamodt R, Bondi J, Andersen SN, Bakka A, Bukholm G, Bukholm IR (2010) The prognostic impact of protein expression of E-cadherin–catenin complexes differs between rectal and colon carcinoma. Gastroenterol Res Pract. doi:10.1155/2010/616023 PubMed

Bacic B, Haller H, Mrklic I, Kosta V, Caric A, Tomic S (2013) Prognostic role of E-cadherin in patients with advanced serous ovarian cancer. Arch Gynecol Obstet 287(6):1219–1224. doi:10.1007/s00404-012-2684-9 PubMedCrossRef

Bettendorf O, Piffko J, Bankfalvi A (2004) Prognostic and predictive factors in oral squamous cell cancer: important tools for planning individual therapy? Oral Oncol 40(2):110–119PubMedCrossRef

Bondi J, Bukholm G, Nesland JM, Bakka A, Bukholm IR (2006) An increase in the number of adhesion proteins with altered expression is associated with an increased risk of cancer death for colon carcinoma patients. Int J Colorectal Dis 21(3):231–237. doi:10.1007/s00384-005-0762-1 PubMedCrossRef

Brinkman BM, Wong DT (2006) Disease mechanism and biomarkers of oral squamous cell carcinoma. Curr Opin Oncol 18(3):228–233. doi:10.1097/01.cco.0000219250.15041.f8 PubMedCrossRef

Brooks CL, Gu W (2003) Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 15(2):164–171PubMedCrossRef

Cheng AN, Jiang SS, Fan CC, Lo YK, Kuo CY, Chen CH, Liu YL, Lee CC, Chen WS, Huang TS, Wang TY, Lee AY (2013) Increased Cdc7 expression is a marker of oral squamous cell carcinoma and overexpression of Cdc7 contributes to the resistance to DNA-damaging agents. Cancer Lett 337(2):218–225. doi:10.1016/j.canlet.2013.05.008 PubMedCrossRef

Davidson B, Gotlieb WH, Ben-Baruch G, Nesland JM, Bryne M, Goldberg I, Kopolovic J, Berner A (2000) E-cadherin complex protein expression and survival in ovarian carcinoma. Gynecol Oncol 79(3):362–371. doi:10.1006/gyno.2000.5964 PubMedCrossRef

Dayan D, Vered M (2013) Is immuno-expression of E-cadherin really a prognostic factor in head and neck cancer? Oral Oncol 49(3):e5. doi:10.1016/j.oraloncology.2012.10.007 PubMedCrossRef

Department-of-Health (ed) (2009) Cancer registry annual report in Taiwan. Department of Health, Taipei, Taiwan

Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, Lopes CS (2004) Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas. Ann Oncol 15(10):1535–1542. doi:10.1093/annonc/mdh387 PubMedCrossRef

Ho CM, Cheng WF, Lin MC, Chen TC, Huang SH, Liu FS, Chien CC, Yu MH, Wang TY, Hsieh CY (2010) Prognostic and predictive values of E-cadherin for patients of ovarian clear cell adenocarcinoma. Int J Gynecol Cancer 20(9):1490–1497. doi:10.1111/IGC.0b013e3181e68a4d PubMed

Huber GF, Zullig L, Soltermann A, Roessle M, Graf N, Haerle SK, Studer G, Jochum W, Moch H, Stoeckli SJ (2011) Down regulation of E-cadherin (ECAD)—a predictor for occult metastatic disease in sentinel node biopsy of early squamous cell carcinomas of the oral cavity and oropharynx. BMC Cancer 11(217):211–218. doi:10.1186/1471-2407-11-217

Hung KF, Chang CS, Liu CJ, Lui MT, Cheng CY, Kao SY (2006) Differential expression of E-cadherin in metastatic lesions comparing to primary oral squamous cell carcinoma. J Oral Pathol Med 35(10):589–594. doi:10.1111/j.1600-0714.2006.00474.x PubMedCrossRef

Hung JJ, Yang MH, Hsu HS, Hsu WH, Liu JS, Wu KJ (2009) Prognostic significance of hypoxia-inducible factor-1alpha, TWIST1 and Snail expression in resectable non-small cell lung cancer. Thorax 64(12):1082–1089. doi:10.1136/thx.2009.115691 PubMedCrossRef

Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S, Baba H, Mori M (2010) Epithelial–mesenchymal transition in cancer development and its clinical significance. Cancer Sci 101(2):293–299. doi:10.1111/j.1349-7006.2009.01419.x PubMedCrossRef

Kim NH, Kim HS, Li XY, Lee I, Choi HS, Kang SE, Cha SY, Ryu JK, Yoon D, Fearon ER, Rowe RG, Lee S, Maher CA, Weiss SJ, Yook JI (2011) A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial–mesenchymal transition. J Cell Biol 195(3):417–433. doi:10.1083/jcb.201103097 PubMedCrossRef

Koensgen D, Freitag C, Klaman I, Dahl E, Mustea A, Chekerov R, Braicu I, Lichtenegger W, Sehouli J (2010) Expression and localization of E-cadherin in epithelial ovarian cancer. Anticancer Res 30(7):2525–2530PubMed

Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, Zhang X, Chua CW, Chan KW, Chan FL, Glackin C, Wong YC, Wang X (2005) Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 65(12):5153–5162. doi:10.1158/0008-5472.can-04-3785 PubMedCrossRef

Lim J, Kim JH, Paeng JY, Kim MJ, Hong SD, Lee JI, Hong SP (2005) Prognostic value of activated Akt expression in oral squamous cell carcinoma. J Clin Pathol 58(11):1199–1205. doi:10.1136/jcp.2004.024786 PubMedCrossRef

Lim SO, Kim H, Jung G (2010) p53 inhibits tumor cell invasion via the degradation of snail protein in hepatocellular carcinoma. FEBS Lett 584(11):2231–2236. doi:10.1016/j.febslet.2010.04.006 PubMedCrossRef

Liu LK, Jiang XY, Zhou XX, Wang DM, Song XL, Jiang HB (2010) Upregulation of vimentin and aberrant expression of E-cadherin/beta-catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome. Mod Pathol 23(2):213–224. doi:10.1038/modpathol.2009.160 PubMedCrossRef

Lydiatt WM, Shah JP, Hoffman HT (2001) AJCC stage groupings for head and neck cancer: should we look at alternatives? A report of the head and neck sites task force. Head Neck 23(8):607–612PubMedCrossRef

Martin TA, Goyal A, Watkins G, Jiang WG (2005) Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann Surg Oncol 12(6):488–496. doi:10.1245/aso.2005.04.010 PubMedCrossRef

Mignogna MD, Fedele S, Lo Russo L (2004) The world cancer report and the burden of oral cancer. Eur J Cancer Prev 13(2):139–142PubMedCrossRef

Moore SR, Johnson NW, Pierce AM, Wilson DF (2000) The epidemiology of mouth cancer: a review of global incidence. Oral Dis 6(2):65–74PubMedCrossRef

Muller PA, Vousden KH, Norman JC (2011) p53 and its mutants in tumor cell migration and invasion. J Cell Biol 192(2):209–218. doi:10.1083/jcb.201009059 PubMedCrossRef

Nijkamp MM, Span PN, Hoogsteen IJ, van der Kogel AJ, Kaanders JH, Bussink J (2011) Expression of E-cadherin and vimentin correlates with metastasis formation in head and neck squamous cell carcinoma patients. Radiother Oncol 99(3):344–348. doi:10.1016/j.radonc.2011.05.066 PubMedCrossRef

Parkin DM, Pisani P, Ferlay J (1999) Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80(6):827–841PubMedCrossRef

Peinado H, Olmeda D, Cano A (2007) Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7(6):415–428. doi:10.1038/nrc2131 PubMedCrossRef

Ren D, Wang M, Guo W, Zhao X, Tu X, Huang S, Zou X, Peng X (2013) Wild-type p53 suppresses the epithelial–mesenchymal transition and stemness in PC-3 prostate cancer cells by modulating miR145. Int J Oncol 42(4):1473–1481. doi:10.3892/ijo.2013.1825 PubMed

Richmond PJ, Karayiannakis AJ, Nagafuchi A, Kaisary AV, Pignatelli M (1997) Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival. Cancer Res 57(15):3189–3193PubMed

Rosivatz E, Becker I, Specht K, Fricke E, Luber B, Busch R, Hofler H, Becker KF (2002) Differential expression of the epithelial–mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol 161(5):1881–1891. doi:10.1016/s0002-9440(10)64464-1 PubMedCrossRef

Shibata K, Kajiyama H, Ino K, Terauchi M, Yamamoto E, Nawa A, Nomura S, Kikkawa F (2008) Twist expression in patients with cervical cancer is associated with poor disease outcome. Ann Oncol 19(1):81–85. doi:10.1093/annonc/mdm344 PubMedCrossRef

Thiery JP (2002) Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer 2(6):442–454. doi:10.1038/nrc822 PubMedCrossRef

Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial–mesenchymal transitions in development and disease. Cell 139(5):871–890. doi:10.1016/j.cell.2009.11.007 PubMedCrossRef

Tseng RC, Lee SH, Hsu HS, Chen BH, Tsai WC, Tzao C, Wang YC (2010) SLIT2 attenuation during lung cancer progression deregulates beta-catenin and E-cadherin and associates with poor prognosis. Cancer Res 70(2):543–551. doi:10.1158/0008-5472.can-09-2084 PubMedCrossRef

Ueda G, Sunakawa H, Nakamori K, Shinya T, Tsuhako W, Tamura Y, Kosugi T, Sato N, Ogi K, Hiratsuka H (2006) Aberrant expression of beta- and gamma-catenin is an independent prognostic marker in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 35(4):356–361. doi:10.1016/j.ijom.2005.07.023 PubMedCrossRef

Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM, Schalken JA (1994) Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 54(14):3929–3933PubMed

van Oort IM, Tomita K, van Bokhoven A, Bussemakers MJ, Kiemeney LA, Karthaus HF, Witjes JA, Schalken JA (2007) The prognostic value of E-cadherin and the cadherin-associated molecules alpha-, beta-, gamma-catenin and p120ctn in prostate cancer specific survival: a long-term follow-up study. Prostate 67(13):1432–1438. doi:10.1002/pros.20626 PubMedCrossRef

Vousden KH, Lu X (2002) Live or let die: the cell’s response to p53. Nat Rev Cancer 2(8):594–604. doi:10.1038/nrc864 PubMedCrossRef

Wang SP, Wang WL, Chang YL, Wu CT, Chao YC, Kao SH, Yuan A, Lin CW, Yang SC, Chan WK, Li KC, Hong TM, Yang PC (2009) p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat Cell Biol 11(6):694–704. doi:10.1038/ncb1875 PubMedCrossRef

Wu DW, Lee MC, Wang J, Chen CY, Cheng YW, Lee H (2013) DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer. Oncogene. doi:10.1038/onc.2013.107

Yang MH, Wu KJ (2008) TWIST activation by hypoxia inducible factor-1 (HIF-1): implications in metastasis and development. Cell cycle (Georgetown, TX) 7(14):2090–2096CrossRef

Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117(7):927–939. doi:10.1016/j.cell.2004.06.006 PubMedCrossRef

Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, Teng SC, Wu KJ (2008) Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 10(3):295–305. doi:10.1038/ncb1691 PubMedCrossRef

Yang MH, Chen CL, Chau GY, Chiou SH, Su CW, Chou TY, Peng WL, Wu JC (2009) Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology (Baltimore, MD) 50(5):1464–1474. doi:10.1002/hep.23221 CrossRef

Yu Q, Zhang K, Wang X, Liu X, Zhang Z (2010) Expression of transcription factors snail, slug, and twist in human bladder carcinoma. J Exp Clin Cancer Res 29:119. doi:10.1186/1756-9966-29-119 PubMedCrossRef

Yuen HF, Chua CW, Chan YP, Wong YC, Wang X, Chan KW (2007) Significance of TWIST and E-cadherin expression in the metastatic progression of prostatic cancer. Histopathology 50(5):648–658. doi:10.1111/j.1365-2559.2007.02665.x PubMedCrossRef

Zhao Z, Ge J, Sun Y, Tian L, Lu J, Liu M, Zhao Y (2012) Is E-cadherin immunoexpression a prognostic factor for head and neck squamous cell carcinoma (HNSCC)? A systematic review and meta-analysis. Oral Oncol 48(9):761–767. doi:10.1016/j.oraloncology.2012.02.024 PubMedCrossRef

Zhou YN, Xu CP, Han B, Li M, Qiao L, Fang DC, Yang JM (2002) Expression of E-cadherin and beta-catenin in gastric carcinoma and its correlation with the clinicopathological features and patient survival. WJG 8(6):987–993PubMed

Title: Expression of E-cadherin, Twist, and p53 and their prognostic value in patients with oral squamous cell carcinoma
Authors: Chi-Chen Fan
Tao-Yeuan Wang
Yen-An Cheng
Shih Sheng Jiang
Chien-Wen Cheng
Alan Yueh-Luen Lee
Ting-Yu Kao
Publication date: 01-10-2013
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 10/2013
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-013-1499-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2013

Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective

MicroRNAs targeting EGFR signalling pathway in colorectal cancer

The efficacy of nonestrogenic therapy to hot flashes in cancer patients under hormone manipulation therapy: a systematic review and meta-analysis

Rituximab, Ara-C, dexamethasone and oxaliplatin (R-ADOx) is effective for treatment of elderly patients with relapsed mantle cell lymphoma

Doxorubicin induces atypical NF-κB activation through c-Abl kinase activity in breast cancer cells

Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials